FourThought Financial LLC Buys 1,185 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Posted by Defense World Staff on Mar 19th, 2023

FourThought Financial LLC boosted its stake in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 97.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,400 shares of the medical research company’s stock after acquiring an additional 1,185 shares during the period. FourThought Financial LLC’s holdings in Exact Sciences were worth $78,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its holdings in Exact Sciences by 45.7% in the third quarter. Signaturefd LLC now owns 957 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 300 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new stake in shares of Exact Sciences during the 3rd quarter valued at $33,000. National Bank of Canada FI boosted its holdings in shares of Exact Sciences by 72.6% during the 3rd quarter. National Bank of Canada FI now owns 1,189 shares of the medical research company’s stock valued at $39,000 after buying an additional 500 shares in the last quarter. Ronald Blue Trust Inc. bought a new stake in shares of Exact Sciences during the 2nd quarter valued at $91,000. Finally, Northern Oak Wealth Management Inc. boosted its holdings in shares of Exact Sciences by 33.8% during the 2nd quarter. Northern Oak Wealth Management Inc. now owns 1,585 shares of the medical research company’s stock valued at $62,000 after buying an additional 400 shares in the last quarter. Institutional investors own 90.30% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Sarah Condella sold 1,000 shares of the company’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the executive vice president now owns 85,090 shares of the company’s stock, valued at approximately $5,105,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Sarah Condella sold 1,000 shares of the company’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the executive vice president now owns 85,090 shares of the company’s stock, valued at approximately $5,105,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jacob A. Orville sold 6,832 shares of the company’s stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $60.29, for a total transaction of $411,901.28. Following the sale, the insider now directly owns 16,423 shares of the company’s stock, valued at approximately $990,142.67. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,126 shares of company stock valued at $3,915,586. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on EXAS. SVB Leerink boosted their target price on shares of Exact Sciences from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, January 12th. StockNews.com began coverage on shares of Exact Sciences in a report on Thursday. They set a “hold” rating on the stock. Benchmark lifted their price target on Exact Sciences from $54.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday. Credit Suisse Group reaffirmed a “neutral” rating and issued a $70.00 price target on shares of Exact Sciences in a research report on Wednesday, February 22nd. Finally, BTIG Research lowered their price target on Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, February 22nd. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $74.14.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS opened at $63.44 on Friday. Exact Sciences Co. has a fifty-two week low of $29.27 and a fifty-two week high of $76.94. The business has a 50-day simple moving average of $65.30 and a two-hundred day simple moving average of $48.98. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.38 and a quick ratio of 2.09.

Exact Sciences (NASDAQ:EXAS – Get Rating) last issued its earnings results on Tuesday, February 21st. The medical research company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.18. Exact Sciences had a negative return on equity of 19.76% and a negative net margin of 29.92%. The business had revenue of $553.00 million during the quarter, compared to analyst estimates of $525.61 million. During the same quarter in the previous year, the firm earned ($1.28) EPS. Exact Sciences’s revenue was up 16.7% on a year-over-year basis. Equities research analysts forecast that Exact Sciences Co. will post -2.76 EPS for the current fiscal year.

Exact Sciences Profile

(Get Rating)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.